Study to Explore the Effects of Probiotics on Endotoxin Levels in Type 2 Diabetes Mellitus Patients
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Probiotics, which are believed to be health promoting live microorganisms, have been reported to influence circulating endotoxin levels. Ingestion of the live cultures may alter gut mircobiota in a beneficial manner to reduce inflammation; although their mechanism and influence to reduce inflammation in T2DM is not established for this disease state. Therefore, the aim of this study is to (1) characterize the beneficial effects of probiotics on circulating endotoxin levels and other biomarkers related to systemic low-grade inflammation in patients with T2DM; (2) Compare circulating endotoxin levels and inflammatory cytokine levels between patients treated with probiotics or placebo to examine the beneficial effects of probiotics on reducing the inflammatory status, through assessment of systemic markers (adipokines, endotoxin, cytokines); (3) to examine the effects of probiotics on gut microflora in order to understand the mechanism for such change in inflammatory status. To achieve this, 120 consenting adult Saudis, naïve or newly diagnosed T2DM patients without co-morbidities, will be enrolled in this clinical trial and randomized to receive twice-daily placebo or probiotics for 26 weeks in a double-blind manner. Glycemic inflammatory markers will be measured and fecal samples analysed, interventions will be done at baseline, 4, 8, 12 and 26 weeks. It is envisaged that probiotics will induce beneficial changes in gut mircobiota, reduce the systemic inflammatory state through altering systemic endotoxin levels and, as such, reduce the systemic inflammatory response observed in T2DM subjects. This will have a fundamental impact on how we should treat the inflammatory component of T2DM, particularly once the results are verified in a larger cohort of patients, as this could have very dramatic effects on how we treat patients with T2DM. Reducing the pathogenesis of T2DM by dampening the inflammatory response, which may also impact on insulin resistance status and health of the individual, will have clear benefits. This could have profound effects on preventative T2DM management, as well as current T2DM care without excessive cost for the wider Saudi health economy.
| Condition | Intervention |
|---|---|
|
Diabetes Mellitus Type 2 |
Dietary Supplement: Probiotics Dietary Supplement: Placebo |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Supportive Care |
| Official Title: | A 26-week, Randomized, Double-blind, Placebo-controlled Study to Explore the Effects of Probiotics on Endotoxin Levels in Patients With Type 2 Diabetes Mellitus |
- effects of probiotics on endotoxin levels in patients with T2DM [ Time Frame: 1 year ] [ Designated as safety issue: No ]Exploration of baseline characteristics and determination of associations between nutritional habits, gut flora and levels of endotoxin/inflammatory markers at baseline and subsequent follow ups
- effects of probiotics on gut microflora [ Time Frame: 1 year ] [ Designated as safety issue: No ]Determine changes from baseline in the amount of probiotics, all anaerobic bacteria and short-chain fatty acids (e.g., propionate and butyrate) present in fecal samples.
- Effects of probiotics on insulin resistance [ Time Frame: 1 year ] [ Designated as safety issue: No ]Determine changes from baseline in serum levels of glucose, HbA1C, insulin and C-peptide
| Estimated Enrollment: | 120 |
| Study Start Date: | March 2013 |
| Estimated Study Completion Date: | March 2015 |
| Estimated Primary Completion Date: | March 2015 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Probiotics
Probitoics
|
Dietary Supplement: Probiotics
Administration of probiotics daily for 26 weeks and compared to placebo
Other Name: Ecologic Metabolic
|
|
Placebo Comparator: Placebo
Placebo
|
Dietary Supplement: Placebo
Administration of placebo daily for 26 weeks and compared to probiotics group
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 20 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Stable and well controlled T2DM (HbA1c < 7.5% and no change in oral antidiabetic medications during the last 6 months)
- Age 20-75 years
- Provision of written informed consent
Exclusion Criteria:
- Chronic gastrointestinal disease (except IBS)
- Systemic antibiotics within 6 weeks before inclusion
- Use of probiotics within 3 months before inclusion (Appendix A lists products currently marketed internationally and available to purchase in Saudi Arabia)
- Regular intake of insulin or insulin analogs, antibiotics or probiotics, antacids, H2-receptor blockers, proton pump inhibiters, loperamide, cholestryramine, ω3 supplements, fibrates, corticosteroids or sex steroids
- Daily alcohol consumption > 30 g
- Significant immunodeficiency
- Known cardiac valvular disease
- Breast-feeding or pregnant
- Non-Arab ethnicity
- Participation in another clinical trial within the last 6 months
- Legal incapability
Contacts and Locations| Contact: Nasser M Al-Daghri, PhD | 0096614675939 | ndaghri@ksu.edu.sa |
| Contact: Shaun Louie B Sabico, MD | 00966534689404 | s.l.sabico@warwick.ac.uk |
| Saudi Arabia | |
| Biomarkers Research Program, King Saud university | Not yet recruiting |
| Riyadh, Saudi Arabia, 11451 | |
| Contact: Nasser Al-Daghri, PhD 00966534689404 ndaghri@ksu.edu.sa | |
| Contact: Shaun Sabico, MD 0096614675939 s.l.sabico@warwick.ac.uk | |
| Sub-Investigator: Shaun Sabico, MD | |
| Study Chair: | Nasser Al-Daghri, PhD | King Saud University |
| Principal Investigator: | Majed Alokail, PhD | King Saud University |
More Information
No publications provided
| Responsible Party: | Nasser Al-Daghri, Professor, King Saud University |
| ClinicalTrials.gov Identifier: | NCT01765517 History of Changes |
| Other Study ID Numbers: | 11-MED2114-02, NPST_Alokail |
| Study First Received: | January 1, 2013 |
| Last Updated: | January 8, 2013 |
| Health Authority: | Saudi Arabia: Ministry of Health |
Keywords provided by King Saud University:
|
Diabetes Mellitus |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
ClinicalTrials.gov processed this record on May 21, 2013